Australia - englanti - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hypromellose; sorbitan stearate; magnesium stearate; titanium dioxide; purified talc; triacetin; iron oxide yellow - apo-tadalafil is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hormosan pharma gesellschaft mit beschränkter haftung - geschäftsanschrift - (3068808) - tadalafil; tadalafil - filmtablette - tadalafil (29976) 4,63 milligramm; tadalafil (29976) 0,37 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hormosan pharma gesellschaft mit beschränkter haftung - geschäftsanschrift - (3068808) - tadalafil; tadalafil - filmtablette - tadalafil (29976) 18,5 milligramm; tadalafil (29976) 1,5 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hormosan pharma gesellschaft mit beschränkter haftung - geschäftsanschrift - (3068808) - tadalafil; tadalafil - filmtablette - tadalafil (29976) 9,25 milligramm; tadalafil (29976) 0,75 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hormosan pharma gesellschaft mit beschränkter haftung - geschäftsanschrift - (3068808) - tadalafil; tadalafil - filmtablette - tadalafil (29976) 2,31 milligramm; tadalafil (29976) 0,19 milligramm

Saksa - saksa - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

alembic pharmaceuticals europe limited (8146921) - tadalafil; tadalafil - filmtablette - tadalafil (29976) 18,5 milligramm; tadalafil (29976) 1,5 milligramm

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; colloidal anhydrous silica; povidone; poloxamer; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; microcrystalline cellulose; sodium lauryl sulfate; poloxamer; colloidal anhydrous silica; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - englanti - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; colloidal anhydrous silica; povidone; poloxamer; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Yhdysvallat - englanti - NLM (National Library of Medicine)

solco healthcare us, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil tablets are indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability. studies establishing effectiveness included predominately patients with nyha functional class ii – iii symptoms and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (23%). tadalafil tablets are contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. do not use nitrates within 48 hours of the last dose of tadalafil tablets. tadalafil tablets potentiate the hypotensive effect of nitrates. this potentiation is thought to result from the combined effects of nitrates and tadalafil tablets on the nitric oxide/cgmp pathway [see clinical pharmacology (12.2)] . coadministration of gc stimulators such as riociguat with tadalafil tablets are contraindicated. tadalafil tablets may potentiate the hypotensive effects of gc stimulators. tadalafil tablets are contraindicated in patients with a k